<abstract xmlns="http://www.w3.org/1999/xhtml"> Objective. Trans-chalcone is a chalcone with hepatoprotective and anti-inflammatory effects. However, the mechanism of these positive effects, especially on miR-451 as an inflammatory regulator, is poorly understood. In this regard, this microRNA (miRNA) acts by inhibition of hepatic interleukin-8 (IL-8) production in the liver which is one of the main proinflammatory cytokines. Th is study for the first time examined the effect of trans-chalcone on miR-451/IL-8 pathway. Methods. In present study, 21 male rats were randomly divided into 3 groups (n=7 per each group): control which received solvent (NS), groups 2 (N2T) and 3 (N6T), which received transchalcone for 2 and 6 weeks, respectively. Hepatic level of miR-451 was measured by qRT-PCR. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as well as hepatic level of IL-8 protein were measured. Results. Trans-chalcone decreased hepatic level of IL-8 protein and serum level of ALT aft er 2 weeks of treatment without significant change in hepatic miR-451. Moreover, it increased hepatic level of miR-451 and reduced hepatic IL-8 as well as AST and ALT aft er 6 weeks. Conclusion. Based on the results of present study, miR-451/IL-8 pathway is a possible mechanism for hepatoprotective action of trans-chalcone in long-term.</abstract>

Effect of trans-chalcone on hepatic IL-8 through the regulation of miR-451 in male rats

<abstract xmlns="http://www.w3.org/1999/xhtml"> Objective. We investigated the effects of magnesium supplementation on glucose tolerance, insulin sensitivity, oxidative stress as well as the concentration of insulin receptor and glucose transporter-4 in streptozotocin-nicotinamide induced type-2 diabetic (T2D) rats. Methods. Rats were divided into four groups designated as: 1) control (CTR); 2) diabetic untreated (DU); 3) diabetic treated with 1 mg of Mg/kg diet (Mg1-D); and 4) diabetic treated with 2 mg of Mg/kg diet (Mg2-D). T2D was induced with a single intraperitoneal (i.p.) injection of freshly prepared streptozotocin (55 mg/kg) aft er an initial i.p. injection of nicotinamide (120 mg/kg). Glucose tolerance, insulin sensitivity, lipid profile, malondialdehyde (MAD) and glutathione content, insulin receptors (INSR) and glucose transporter-4 (GLUT4), fasting insulin and glucose levels were measured, and insulin resistance index was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR). Results. Magnesium supplementation improved glucose tolerance and lowered blood glucose levels almost to the normal range. We also recorded a noticeable increase in insulin sensitivity in Mg-D groups when compared with DU rats. Lipid perturbations associated T2D were significantly attenuated by magnesium supplementation. Fasting glucose level was comparable to control values in the Mg-D groups while the HOMA-IR index was significantly lower compared with the DU rats. Magnesium reduced MDA but increased glutathione concentrations compared with DU group. Moreover, INSR and GLUT4 levels were elevated following magnesium supplementation in T2D rats. Conclusion. These findings demonstrate that magnesium may mediate effective metabolic control by stimulating the antioxidant defense, and increased levels of INSR and GLUT4 in diabetic rats.</abstract>

Magnesium upregulates insulin receptor and glucose transporter-4 in streptozotocin-nicotinamide-induced type-2 diabetic rats

<abstract xmlns="http://www.w3.org/1999/xhtml"> Objectives. The deformability of erythrocytes is their ability to change shape in order to pass through the capillaries. Th is is necessary for quality of microcirculation and sufficient delivery of oxygen to the tissues. Th e aim of our study was to investigate the possible spontaneous changes in the erythrocyte deformability during day and evaluation of the possible direct effects of melatonin (hormone involved in regulation of biorhythms) on the erythrocyte deformability. Methods. Samples of capillary blood were taken from 12 healthy volunteers in the morning (8:00) and early in the evening (16:30). Determination of erythrocyte deformability was done based on the measurement of their filtrability. It was measured immediately aft er the sample collection and 2-hour lasting incubation without or with melatonin (2000 μmol/L). Results. Erythrocyte deformability was significantly lower in the morning (filtrability index: 0.68±0.01 morning vs. 0.71±0.01 early evening, p&lt;0.05). Th e incubation of blood samples with melatonin did not have impact on deformability. Conclusions. We suggest the presence of diurnal changes in erythrocyte deformability with worse values in the morning that may contribute to higher risk of ischemic attacks in the morning hours. Direct in vitro effect of melatonin on deformability was not observed, but possible in vivo effects cannot be excluded.</abstract>

Changes in erythrocyte deformability during day and possible role of melatonin

<abstract xmlns="http://www.w3.org/1999/xhtml"> Objective. Histone deacytylase inhibitors (HDACis) inhibit the deacetylation of the lysine residue of proteins, including histones, and regulate the transcription of a variety of genes. Recently, HDACis have been used clinically as anti-cancer drugs and possible anti-diabetic drugs. Even though HDACis have been proven to protect the cytokine-induced damage of pancreatic beta cells, evidence also shows that high doses of HDACis are cytotoxic. In the present study, we, therefore, investigated the eff ect of HDACis on insulin secretion in a pancreatic beta cell line. Methods. Pancreatic beta cells MIN6 were treated with selected HDACis (trichostatin A, TSA; valproic acid, VPA; and sodium butyrate, NaB) in medium supplemented with 25 mM glucose and 13% heat-inactivated fetal bovine serum (FBS) for indicated time intervals. Protein expression of Pdx1 and Mafa in MIN6 cells was demonstrated by immunohistochemistry and immunocytochemistry, expression of Pdx1 and Mafa genes was measured by quantitative RT-PCR method. Insulin release from MIN6 cells and insulin cell content were estimated by ELISA kit. Superoxide production in MIN6 cells was measured using a Total ROS/Superoxide Detection System. Results. TSA, VPA, and NaB inhibited the expression of Pdx1 and Mafa genes and their products. TSA treatment led to beta cell malfunction, characterized by enhanced insulin secretion at 3 and 9 mM glucose, but impaired insulin secretion at 15 and 25 mM glucose. Th us, TSA induced dysregulation of the insulin secretion mechanism. TSA also enhanced reactive oxygen species production in pancreatic beta cells. Conclusions. Our results showed that HDACis caused failure to suppress insulin secretion at low glucose concentrations and enhance insulin secretion at high glucose concentrations. In other words, when these HDACis are used clinically, high doses of HDACis may cause hypoglycemia in the fasting state and hyperglycemia in the fed state. When using HDACis, physicians should, therefore, be aware of the capacity of these drugs to modulate the insulin secretory capacity of pancreatic beta cells.</abstract>

High dose of histone deacetylase inhibitors affects insulin secretory mechanism of pancreatic beta cell line

<abstract xmlns="http://www.w3.org/1999/xhtml"> Objectives. The aim of this study was to present up to date information concerning the diagnosis and treatment of primary aldosteronism (PA). PA is the most common cause of endocrine hypertension. It has been reported up to 24% of selective referred hypertensive patients. Methods. We did a search in Pub-Med and Google Scholar using the terms: PA, hyperaldosteronism, idiopathic adrenal hyperplasia, diagnosis of PA, mineralocorticoid receptor antagonists, adrenalectomy, and surgery. We also did cross-referencing search with the above terms. We had divided our study into five sections: Introduction, Diagnosis, Genetics, Treatment, and Conclusions. We present our results in a question and answer fashion in order to make reading more interesting. Results. PA should be searched in all high-risk populations. The gold standard for diagnosis PA is the plasma aldosterone/plasma renin ratio (ARR). If this test is positive, then we proceed with one of the four confirmatory tests. If positive, then we proceed with a localizing technique like adrenal vein sampling (AVS) and CT scan. If the lesion is unilateral, after proper preoperative preparation, we proceed, in adrenalectomy. If the lesion is bilateral or the patient refuses or is not fit for surgery, we treat them with mineralocorticoid receptor antagonists, usually spironolactone. Conclusions. Primary aldosteronism is the most common and a treatable case of secondary hypertension. Only patients with unilateral adrenal diseases are eligible for surgery, while patients with bilateral and non-surgically correctable PA are usually treated by mineralocorticoid receptor antagonist (MRA). Thus, the distinction between unilateral and bilateral aldosterone hypersecretion is crucial.</abstract>

A short review of primary aldosteronism in a question and answer fashion

<abstract xmlns="http://www.w3.org/1999/xhtml"> Pheochromocytomas and paragangliomas (PPGLs) are tumors arising from the adrenal medulla and sympathetic/parasympathetic paraganglia, respectively. According to Th e Cancer Genome Atlas (TCGA), approximately 40% of PPGLs are due to germ line mutations in one of 16 susceptibility genes, and a further 30% are due to somatic alterations in at least seven main genes (VHL, EPAS1, CSDE1, MAX, HRAS, NF1, RET, and possibly KIF1B). Th e diagnosis of malignant PPGL was straight forward in most cases as it was defined as presence of PPGL in non-chromaffin tissues. Accordingly, there is an extreme need for new diagnostic marker(s) to identify tumors with malignant prospective. Th e aim of this study was to review all suggested genetic and epigenetic alterations that are remarkably different between benign and malignant PPGLs. It seems that more than two genetic mutation clusters in PPGLs and other genetic and methylation biomarkers could be targeted for malignancy discrimination in different studies.</abstract>

Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs)

AHEAD OF PRINT

Volume 58 (2024): Issue 1 (January 2024)

Volume 57 (2023): Issue 1 (January 2023)

Volume 56 (2022): Issue 4 (October 2022)

Volume 56 (2022): Issue 3 (July 2022)

Volume 56 (2022): Issue 2 (April 2022)

Volume 56 (2022): Issue 1 (January 2022)

Volume 55 (2021): Issue 4 (October 2021)

Volume 55 (2021): Issue 3 (July 2021)

Volume 55 (2021): Issue 2 (April 2021)

Volume 55 (2021): Issue 1 (January 2021)

Volume 54 (2020): Issue 4 (October 2020)

Volume 54 (2020): Issue 3 (July 2020)

Volume 54 (2020): Issue 2 (April 2020)

Volume 54 (2020): Issue 1 (January 2020)

Volume 53 (2019): Issue 4 (October 2019)

Volume 53 (2019): Issue 3 (July 2019)

Volume 53 (2019): Issue 2 (April 2019)

Volume 53 (2019): Issue 1 (January 2019)

Volume 52 (2018): Issue 4 (October 2018)

Volume 52 (2018): Issue 3 (July 2018)

Volume 52 (2018): Issue 2 (April 2018)

Volume 52 (2018): Issue 1 (January 2018)

Volume 51 (2017): Issue 4 (October 2017)

Volume 51 (2017): Issue 3 (July 2017)

Volume 51 (2017): Issue 2 (April 2017)

Volume 51 (2017): Issue 1 (January 2017)

Volume 50 (2016): Issue 4 (October 2016)

Volume 50 (2016): Issue 3 (July 2016)

Volume 50 (2016): Issue 2 (April 2016)

Volume 50 (2016): Issue 1 (January 2016)

Endocrine Regulations

 Endocrine Regulations (from 1967 to 1990 as Endocrinologia Experimentalis), an open access, peer reviewed international journal, welcomes the submission of original research papers and review articles from traditionally recognized fields of experimental and clinical endocrinology, including neuroendocrinology, thyroid and adrenal gland research, metabolism and diabetes, reproduction, and genetic endocrinology. Basic and pathophysiological studies using animal models, and research studies at cellular and molecular level are also considered, as well as human sample studies, where this is the experimental model of choice. Clinical case reports are also welcome.   Why subscribe and read    source of high quality basic and clinical research (original research papers, review articles, case reports, short communications) related to interdisciplinary endocrinology fields,   peer-reviewed by international experts,   available in electronic format,   free of charge access (open access) for readers    Why submit   Endocrine Regulations is an open access journal that publishes papers, which are accessible to international audience and indexed by abstracting and full-text databases including PubMed, Scopus, Embase, etc.The manuscripts are submitted via Editorial Manager system, which reduces the editorial processing and reviewing time of manuscripts, and shortening the overall publication process.       Archiving   Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.   Plagiarism Policy   The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 